These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19642460)

  • 21. The emerging role of cetuximab in head and neck cancer: a 2007 perspective.
    Panikkar RP; Astsaturov I; Langer CJ
    Cancer Invest; 2008 Feb; 26(1):96-103. PubMed ID: 18181051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of cetuximab in the management of head and neck cancers.
    Kabolizadeh P; Kubicek GJ; Heron DE; Ferris RL; Gibson MK
    Expert Opin Biol Ther; 2012 Apr; 12(4):517-28. PubMed ID: 22413826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
    Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
    Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.
    Moon C; Chae YK; Lee J
    Exp Biol Med (Maywood); 2010 Aug; 235(8):907-20. PubMed ID: 20562132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of efficacy and safety of cetuximab and bevacizumab-based monoclonal antibodies in head and neck cancer.
    Khadela A; Shah Y; Mistry P; Mansuri M; Sureja D; Bodiwala K
    Med Oncol; 2022 Dec; 40(1):66. PubMed ID: 36583766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cetuximab in cancers of the lung and head & neck.
    Kim ES; Vokes EE; Kies MS
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):61-7. PubMed ID: 14981582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
    Eder J; Simonitsch-Klupp I; Trautinger F
    Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cetuximab in squamous cell head and neck carcinomas.
    Gebbia V; Giuliani F; Valori VM; Agueli R; Colucci G; Maiello E
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi5-7. PubMed ID: 17591832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Role of targeted therapy in the treatment of squamous cell head and neck cancer].
    Gyergyay F
    Magy Onkol; 2007; 51(2):155-7. PubMed ID: 17660872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?
    Bernier J; Schneider D
    Eur J Cancer; 2007 Jan; 43(1):35-45. PubMed ID: 17098420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
    Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Oncological treatment modalities in head and neck cancer].
    Saarilahti K; Lindholm P
    Duodecim; 2011; 127(18):1979-85. PubMed ID: 22034736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
    Bourhis J; Lefebvre JL; Vermorken JB
    Eur J Cancer; 2010 Jul; 46(11):1979-89. PubMed ID: 20561781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck.
    Burtness B
    J Clin Oncol; 2005 Aug; 23(24):5440-2. PubMed ID: 16009959
    [No Abstract]   [Full Text] [Related]  

  • 37. Manageable early toxicity of cetuximab concurrent with radical radiotherapy for locally advanced head and neck cancer.
    Wieczorek A; Hamid A; O'Toole L
    Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):496. PubMed ID: 21482459
    [No Abstract]   [Full Text] [Related]  

  • 38. Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.
    Teoh DC; Rodger S; Say J; Hartley A
    Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):717. PubMed ID: 18757187
    [No Abstract]   [Full Text] [Related]  

  • 39. Should cetuximab replace cisplatin in head and neck cancer?
    Rowan K
    J Natl Cancer Inst; 2010 Jan; 102(2):74-6, 78. PubMed ID: 20054019
    [No Abstract]   [Full Text] [Related]  

  • 40. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
    Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Yu CT; Ganul V; Roh JK; Bajetta E; O'Byrne K; de Marinis F; Eberhardt W; Goddemeier T; Emig M; Gatzemeier U;
    Lancet; 2009 May; 373(9674):1525-31. PubMed ID: 19410716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.